AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Coherus BioSciences Plunges 13.73% on Flat Q1 Revenue
Generated by AI AgentAinvest Movers Radar
Tuesday, May 13, 2025 5:10 am ET1min read
On May 13, 2025,
experienced a significant drop of 13.73% in pre-market trading, reflecting investor sentiment amidst recent developments and financial reports.Coherus BioSciences reported its Q1 2025 earnings, revealing a flat revenue of $7.3 million despite a 15% growth in patient demand. The company also initiated a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L HNSCC, with the
readout expected in Q2 2026.The company's strategic shift towards
, including the divestiture of its UDENYCA franchise, has positioned it for future growth. Key financial metrics for the quarter included net revenue from continuing operations of $7.6 million, driven by LOQTORZI sales, and a net loss from continuing operations of $47.4 million, showing an improvement from the previous year’s loss.Coherus BioSciences is actively advancing its oncology pipeline, with ongoing studies for CHS-114 and casdozokitug in various cancer indications. The company is also exploring partnerships to expand LOQTORZI’s label and enhance its market presence. Looking ahead, Coherus BioSciences is poised to leverage its innovative oncology portfolio to drive growth and improve cancer treatment outcomes, with key data milestones anticipated in 2026.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
ALT.O Plunges 5.87%—Uncovering the Hidden Catalyst Behind the Selloff
Dec.16 2025
Babcock & Wilcox's Sudden 7% Drop: What's Behind the Unusual Intraday Move?
Dec.16 2025
Digital Turbine Surges Over 7%—What’s Behind the Intraday Pop?
Dec.16 2025
Digital Turbine (APPS.O) Sees Sharp 7.34% Gain—Unpacking the Drivers Behind the Intraday Surge
Dec.16 2025
Wheels Up (UP.N) Surges 5.6% – What's Behind the Intraday Surge?
Dec.16 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet